ACIU Valuation
AC Immune SA
$
2.520
- Overview
- Forecast
- Valuation
- Earnings
ACIU Relative Valuation
ACIU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACIU is overvalued; if below, it's undervalued.
Historical Valuation
AC Immune SA (ACIU) is now in the Fair zone, suggesting that its current forward PS ratio of 107.11 is considered Fairly compared with the five-year average of -6.64. The fair price of AC Immune SA (ACIU) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：2.46
Fair
-3.44
PE
1Y
3Y
5Y
Trailing
Forward
-2.26
EV/EBITDA
AC Immune SA. (ACIU) has a current EV/EBITDA of -2.26. The 5-year average EV/EBITDA is -11.53. The thresholds are as follows: Strongly Undervalued below -75.19, Undervalued between -75.19 and -43.36, Fairly Valued between 20.30 and -43.36, Overvalued between 20.30 and 52.13, and Strongly Overvalued above 52.13. The current Forward EV/EBITDA of -2.26 falls within the Historic Trend Line -Fairly Valued range.
-1.30
EV/EBIT
AC Immune SA. (ACIU) has a current EV/EBIT of -1.30. The 5-year average EV/EBIT is -2.60. The thresholds are as follows: Strongly Undervalued below -15.04, Undervalued between -15.04 and -8.82, Fairly Valued between 3.62 and -8.82, Overvalued between 3.62 and 9.85, and Strongly Overvalued above 9.85. The current Forward EV/EBIT of -1.30 falls within the Historic Trend Line -Fairly Valued range.
104.01
PS
AC Immune SA. (ACIU) has a current PS of 104.01. The 5-year average PS is 45.62. The thresholds are as follows: Strongly Undervalued below -156.72, Undervalued between -156.72 and -55.55, Fairly Valued between 146.79 and -55.55, Overvalued between 146.79 and 247.96, and Strongly Overvalued above 247.96. The current Forward PS of 104.01 falls within the Historic Trend Line -Fairly Valued range.
-2.94
P/OCF
AC Immune SA. (ACIU) has a current P/OCF of -2.94. The 5-year average P/OCF is -13.34. The thresholds are as follows: Strongly Undervalued below -103.26, Undervalued between -103.26 and -58.30, Fairly Valued between 31.61 and -58.30, Overvalued between 31.61 and 76.57, and Strongly Overvalued above 76.57. The current Forward P/OCF of -2.94 falls within the Historic Trend Line -Fairly Valued range.
-2.59
P/FCF
AC Immune SA. (ACIU) has a current P/FCF of -2.59. The 5-year average P/FCF is -0.62. The thresholds are as follows: Strongly Undervalued below -33.36, Undervalued between -33.36 and -16.99, Fairly Valued between 15.75 and -16.99, Overvalued between 15.75 and 32.11, and Strongly Overvalued above 32.11. The current Forward P/FCF of -2.59 falls within the Historic Trend Line -Fairly Valued range.
AC Immune SA (ACIU) has a current Price-to-Book (P/B) ratio of 2.60. Compared to its 3-year average P/B ratio of 1.71 , the current P/B ratio is approximately 52.34% higher. Relative to its 5-year average P/B ratio of 1.74, the current P/B ratio is about 49.47% higher. AC Immune SA (ACIU) has a Forward Free Cash Flow (FCF) yield of approximately -22.07%. Compared to its 3-year average FCF yield of -13.94%, the current FCF yield is approximately 58.32% lower. Relative to its 5-year average FCF yield of -15.85% , the current FCF yield is about 39.26% lower.
2.68
P/B
Median3y
1.71
Median5y
1.74
-22.73
FCF Yield
Median3y
-13.94
Median5y
-15.85
Competitors Valuation Multiple
The average P/S ratio for ACIU's competitors is 20.41, providing a benchmark for relative valuation. AC Immune SA Corp (ACIU) exhibits a P/S ratio of 104.01, which is 409.67% above the industry average. Given its robust revenue growth of 90.10%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ACIU decreased by 33.33% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 687.00K to 1.31M.
The secondary factor is the Margin Expansion, contributed -51.03%to the performance.
Overall, the performance of ACIU in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is AC Immune SA (ACIU) currently overvalued or undervalued?
AC Immune SA (ACIU) is now in the Fair zone, suggesting that its current forward PS ratio of 107.11 is considered Fairly compared with the five-year average of -6.64. The fair price of AC Immune SA (ACIU) is between to according to relative valuation methord.
What is AC Immune SA (ACIU) fair value?
How does ACIU's valuation metrics compare to the industry average?
What is the current P/B ratio for AC Immune SA (ACIU) as of Sep 19 2025?
What is the current FCF Yield for AC Immune SA (ACIU) as of Sep 19 2025?
What is the current Forward P/E ratio for AC Immune SA (ACIU) as of Sep 19 2025?